Elite in Acute Myeloid Leukemia (AML)
Check Dr. Brenda W. Cooper's experience treating your condition:
About Dr. Brenda W. Cooper

Brenda Cooper is a Hematologist Oncology expert in Cleveland, Ohio. Cooper has been practicing medicine for over 39 years and is rated as an Elite expert by MediFind in the treatment of Acute Myeloid Leukemia (AML). She is also highly rated in 36 other conditions, according to our data. Her top areas of expertise are Acute Myeloid Leukemia (AML), Diffuse Large B-Cell Lymphoma (DLBCL), Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. She is licensed to treat patients in Ohio. Cooper is currently accepting new patients.

Her clinical research consists of co-authoring 57 peer reviewed articles and participating in 26 clinical trials in the past 15 years. In particular, she has co-authored 21 articles and participated in 13 clinical trials in the study of Acute Myeloid Leukemia (AML).


MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Brenda W. Cooper it is best to call her office and ask if your insurance is accepted.

Accepts Medicare

Call to see if your plan is accepted.
11100 Euclid Ave, Cleveland, OH 44106
Other Locations
5885 Landerbrook Dr, Suite 100, Mayfield Heights, OH 44124
3909 Orange Pl, Beachwood, OH 44122
Background & Education
Graduate Institution
Johns Hopkins University School Of Medicine, 1984
Hematology Oncology
Internal Medicine in OH
Hospital Affiliations
University Hospitals Cleveland Medical Center
University Hospitals Geauga Medical Center
University Hospitals Ahuja Medical Center
University Hospitals Richmond Medical Center
University Hospitals Parma Medical Center
University Hospitals Geneva Medical Center
Languages Spoken
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

26 Clinical Trials

A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients With Acute Myeloid Leukemia Who Are at High-Risk for Leukemia Relapse Following Hematopoietic Cell Transplantation
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage
A Long-term Follow-up Study of Patients Who Received VOR33
Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Phase I/II Study of Midostaurin (PKC412) and 5-Azacitidine for Elderly Patients With Acute Myelogenous Leukemia.
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Pilot Study Of Multiple Umbilical Cord Blood Unit Transplantation Following Non-Myeloablative Conditioning In Patients With Hematologic Disorders Or Severe Aplastic Anemia
A Proof of Concept Study of Non-DNA Damaging DNMT1 Depletion Therapy for Myelodysplastic Syndrome
Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies
A Phase I Trial of PS-341 and Fludarabine for Relapsed and Refractory Indolent Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
A Phase I Trial of Combination Bryostatin 1 (NSC 339555) and Vincristine in B-Cell Malignancies
Phase I and Pharmacodynamic Study of SB-715992 in Acute Leukemias
View 20 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
Learn about our expert tiers
Learn more
Similar Doctors